Website
News25/Ratings5
News · 26 weeks35-54%
2025-10-262026-04-19
Mix2490d
- Insider12(50%)
- SEC Filings6(25%)
- Earnings3(13%)
- Other2(8%)
- Analyst1(4%)
Latest news
25 items- SECSEC Form DEFA14A filed by Sanara MedTech Inc.DEFA14A - Sanara MedTech Inc. (0000714256) (Filer)
- SECSEC Form DEFA14A filed by Sanara MedTech Inc.DEFA14A - Sanara MedTech Inc. (0000714256) (Filer)
- SECSEC Form DEF 14A filed by Sanara MedTech Inc.DEF 14A - Sanara MedTech Inc. (0000714256) (Filer)
- INSIDERSEC Form 4 filed by Waldrop Jacob A.4 - Sanara MedTech Inc. (0000714256) (Issuer)
- ANALYSTLake Street initiated coverage on Sanara MedTech with a new price targetLake Street initiated coverage of Sanara MedTech with a rating of Buy and set a new price target of $32.00
- PRSanara MedTech Inc. to Report First Quarter 2026 Financial Results on May 12, 2026FORT WORTH, TX, April 14, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company", "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that it will report its first quarter 2026 financial results on Tuesday, May 12, 2026 before the U.S. financial markets open. The Company will host a conference call and webcast on May 12, 2026 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended March 31, 2026 and hold a question and answer session at the end of the call. The toll-free numbe
- SECSEC Form 10-K filed by Sanara MedTech Inc.10-K - Sanara MedTech Inc. (0000714256) (Filer)
- SECSanara MedTech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Sanara MedTech Inc. (0000714256) (Filer)
- PRSanara MedTech Inc. Reports Fourth Quarter (Unaudited) and Full Year 2025 Financial Results; Reaffirmed Full Year 2026 Financial GuidanceFORT WORTH, TX, March 24, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and reaffirmed its financial guidance for the full year ending December 31, 2026. Fourth Quarter 2025 Financial Summary(1) Net revenue increased 5% to $27.5 million, compared to $26.3 million in the fourth quarter of 2024. As previously disclosed, the Company experienced growt
- INSIDERSEC Form 4 filed by Mackey Ashley M4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERSEC Form 4 filed by Taylor Elizabeth B4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERSEC Form 4 filed by Waldrop Jacob A.4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERSEC Form 4 filed by Yon Seth D4 - Sanara MedTech Inc. (0000714256) (Issuer)
- PRSanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX® Surgical Powder in the Management of Spine Surgery WoundsStudy demonstrates cost savings and improved health outcomes associated with the use of CellerateRX® as an adjunct to the standard of care for high-risk spinal surgery patients, compared to the standard of care alone FORT WORTH, TX, March 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today announced the publication of a peer-reviewed study evaluating the economic and clinical value of CellerateRX® Surgical Powder ("CellerateRX") in the Journ
- INSIDERChief Executive Officer Yon Seth D covered exercise/tax liability with 596 shares, decreasing direct ownership by 0.67% to 87,968 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERAmendment: Chief Executive Officer Yon Seth D covered exercise/tax liability with 414 shares, decreasing direct ownership by 0.47% to 88,564 units (SEC Form 4)4/A - Sanara MedTech Inc. (0000714256) (Issuer)
- PRSanara MedTech Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026FORT WORTH, TX, March 03, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026 before the U.S. financial markets open. The Company will host a conference call and webcast on March 24, 2026 at 8:00 a.m. Eastern Time to discuss the results of the quarter and full year ended December 31, 2025 and hold a question and answer session at the
- INSIDERChief Executive Officer Yon Seth D covered exercise/tax liability with 491 shares, decreasing direct ownership by 0.55% to 88,487 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- SECSanara MedTech Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Sanara MedTech Inc. (0000714256) (Filer)
- INSIDERChief Executive Officer Yon Seth D covered exercise/tax liability with 873 shares, decreasing direct ownership by 0.97% to 88,978 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERChief Operating Officer Waldrop Jacob A. covered exercise/tax liability with 714 shares, decreasing direct ownership by 6% to 10,799 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERChief Financial Officer Taylor Elizabeth B covered exercise/tax liability with 437 shares, decreasing direct ownership by 8% to 4,945 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERController Mackey Ashley M covered exercise/tax liability with 149 shares, decreasing direct ownership by 6% to 2,263 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- PRSanara MedTech Inc. to Participate in the TD Cowen 46th Annual Health Care Conference on March 3rdFORT WORTH, TX, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that management will participate in the TD Cowen 46th Annual Health Care Conference, which is being held at the Boston Marriott Copley Place in Boston, MA from March 2 – 4, 2026. Management will deliver a presentation to investors on Tuesday, March 3 at approximately 9:10 a.m. Eastern Time. The presentation materials for the conference will be posted to the Co
- SECSanara MedTech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Sanara MedTech Inc. (0000714256) (Filer)